Lymphoma
If it’s your first time on this website, please read the disclaimer section.
Oct 05 – Oct 12, 2026
Allogeneic stem cell transplantation in aggressive Adult T cell leukemia/lymphoma: a prospective multicenter study.
BLOOD ADV · Q1 JOURNAL - RANK #13/98
This prospective multicenter trial evaluated the feasibility and outcomes of allogeneic stem cell transplantation (allo-SCT) following frontline chemotherapy in 80 aggressive Adult T-cell leukemia/lymphoma (ATL) patients, with 39 ultimately proceeding to allo-SCT using a Thiotepa-Busulfan-Fludarabine conditioning regimen. Two-year overall survival from first-line therapy was 45%, and time-dependent analysis demonstrated a significant survival benefit for allo-SCT (hazard ratio, 0.32). Three-year overall survival and progression-free survival were both 52%, with one-year non-relapse mortality of 15% and cumulative relapse incidence of 35%; absence of complete or partial response at allo-SCT was the primary risk factor for poor outcomes. The authors conclude that allo-SCT provides benefit in eligible ATL patients, supported by molecular evidence of undetectable tumor clones post-transplant suggesting a potent graft-versus-ATL effect.
10.1182/bloodadvances.2026020323
Aug 31 – Sep 07, 2026
Extended D3 Mesenterectomy in Small Bowel Cancer Treatment: Feasibility and Importance for Staging. First Results of a Prospective Clinical Trial.
WORLD J SURG · Q1 JOURNAL - RANK #70/312
This prospective clinical trial assessed the feasibility and staging implications of extended central (D3) mesenteric lymphadenectomy in 86 patients with small bowel cancer. Surgical techniques included preoperative 3D vascular mapping and standardized D3 resection of mesenteric tissue. D3 lymphadenectomy was achieved in 74 patients (86%), with a 7% reoperation rate (including 3% anastomotic leaks) and no 30-day mortality. Histopathology confirmed 60 small intestinal neuroendocrine tumors (siNETs) among 74 resected cases, with mesenteric lymph node metastases found in 62 patients (87%) and D3-volume metastases in 31 (44%). The authors conclude that D3 mesenterectomy is safe and radical, potentially improving staging accuracy and locoregional control, with subgroup analyses showing higher D3 positivity in proximal ileal siNETs (66%) compared to terminal ileal siNETs (29%).
10.1002/wjs.70550
SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.
BRIT J HAEMATOL · Q1 JOURNAL - RANK #24/98
This randomized phase II trial (SAKK 35/14) prospectively compared rituximab plus placebo versus rituximab plus ibrutinib in 24 months of treatment for previously untreated advanced follicular lymphoma requiring systemic therapy. The primary endpoint, complete remission rate at 24 months, was 36% in the placebo arm and 40% in the ibrutinib arm, showing no statistically significant difference. Three-year progression-free survival was 36% versus 45% (hazard ratio 0.64, p=0.057), while overall survival was approximately 96% in both arms, with manageable higher-grade adverse events but no toxic deaths. The authors concluded that although the primary endpoint was not met, the trend toward improved progression-free survival at the prespecified significance level of 0.1 may indicate potential clinical benefit.
10.1111/bjh.70801
Aug 24 – Aug 31, 2026
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
LANCET HAEMATOL · Q1 JOURNAL - RANK #3/98TOP-TIER
This phase 1, single-arm, multicentre dose-escalation trial evaluated the safety of GLPG5101, a fresh CD19 CAR T-cell therapy with decentralised manufacturing, in 24 patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The primary endpoints were safety (adverse events, serious adverse events, and dose-limiting toxicities) and determination of the recommended phase 2 dose. All 23 patients in the safety analysis experienced grade ≥3 treatment-emergent adverse events, with neutropenia (96%) being most common; five dose-limiting toxicities were reported, and four treatment-related deaths occurred. The recommended phase 2 dose was selected as 110 × 10⁶ viable CAR T-cells, with results supporting the feasibility of decentralised manufacturing and delivery.
10.1016/S2352-3026(26)00192-4
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial.
LANCET HAEMATOL · Q1 JOURNAL - RANK #3/98TOP-TIER
This open-label, randomized, controlled phase 2-3 trial (ALLIANCE A051701) enrolled 73 patients with newly diagnosed double-hit lymphoma from 41 US sites to receive either DA-EPOCH-R alone (n=36) or with venetoclax (n=37). The primary endpoint was progression-free survival (PFS) in the modified intent-to-treat population. Median PFS was 28.4 months (95% CI 5.2-NE) in the DA-EPOCH-R group versus 7.7 months (95% CI 4.7-NE) in the venetoclax group (HR 1.13, 95% CI 0.53-2.37; p=0.75). The trial was closed early due to excess mortality on treatment in the venetoclax arm (6 deaths vs 1), with 24-month overall survival of 52% (95% CI 33-68) versus 72% (95% CI 52-85) (HR 2.49, 95% CI 1.03-6.04; p=0.038). The addition of venetoclax to DA-EPOCH-R was associated with increased toxicity and worse survival, and the authors conclude the DA-EPOCH-R outcomes serve as a benchmark for future trials.
10.1016/S2352-3026(26)00191-2
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.
LANCET HAEMATOL · Q1 JOURNAL - RANK #3/98TOP-TIER
This open-label, multicenter, phase 1b/2 trial evaluated epcoritamab plus rituximab-lenalidomide as first-line treatment for follicular lymphoma. Forty-one patients were enrolled and treated; the overall response rate was 95% (39/41) at a median follow-up of 35.9 months. Grade 3-4 adverse events included neutropenia (49%), infections (29%), and COVID-19 (15%); three treatment-related deaths occurred. The authors concluded that this chemotherapy-free combination shows high activity and warrants further investigation.
10.1016/S2352-3026(26)00198-5
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.
BLOOD · Q1 JOURNAL - RANK #2/98TOP-TIER
This phase 1 clinical trial evaluated soquelitinib, a selective covalent ITK inhibitor, in 75 patients with relapsed/refractory T cell lymphomas using a dose-escalation design followed by an expansion cohort. The study assessed safety, target occupancy, and antitumor activity, with no dose-limiting toxicities observed up to 600mg BID and >80% target occupancy achieved at 200mg BID. At this dose, durable complete and partial responses were seen in 37% of patients with 1-3 prior therapies, while no responses occurred in patients with >3 prior lines. The authors conclude that soquelitinib demonstrates antitumor activity in T cell lymphomas with a mechanism involving Th1 skewing and reduction of T cell exhaustion.
10.1182/blood.2026034704
Aug 17 – Aug 24, 2026
Clinical and molecular prognostic factors in newly diagnosed pediatric T-cell lymphoblastic lymphoma: a prospective, multicenter, single-arm phase 2 clinical trial.
WORLD J PEDIATR · Q1 JOURNAL - RANK #9/191
This prospective, multicenter, single-arm phase 2 clinical trial evaluated the response-adjusted CCCG-LBL-2016 protocol in 163 newly diagnosed pediatric T-cell lymphoblastic lymphoma patients, collecting clinical and laboratory data from seven centers. A sub-cohort of 23 patients underwent exploratory genomic analyses including targeted next-generation sequencing and RNA sequencing. The 3-year overall survival (OS) and event-free survival (EFS) were 78.6%±3.3% and 73.9%±3.5%, respectively, with significantly worse outcomes in the escalated high-risk group (R3: OS 58.6%±9.1%, EFS 48.3%±9.1%). Exploratory multivariable Cox regression identified CDKN2A alteration as associated with increased risk of progression or recurrence (hazard ratio=35.89, 95% CI: 3.07-419, P=0.004), suggesting molecular risk factors may improve future risk stratification. The authors concluded that response-adjusted treatment improved overall prognosis, but survival remains poor for patients experiencing progression or recurrence.
10.1007/s12519-026-01058-x